Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 5,231 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Lumbar Spinal Fusions
Interventions: Pregabalin 150 mg, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 21 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Stress, Anxiety
Interventions: Proprietary Blend of Ashwagandha, KSM-66 Ashwagandha root extract, Placebo; Dietary Supplement
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more

Conditions: Schizophrenia
Interventions: SEP-363856, Placebo - Cap; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Little Rock, Arkansas • Garden Grove, California • Pico Rivera, California + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Litchfield Park, Arizona • Phoenix, Arizona • Tempe, Arizona + 23 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 54
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more

Conditions: COVID-19
Interventions: C21, Placebo; Drug
Lead sponsor: Vicore Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Orange, California • Winfield, Illinois • Fort Wayne, Indiana + 3 more

Conditions: Fragile X Syndrome
Interventions: BPN14770/ zatolmilast, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Irvine, California • Orange, California • Sacramento, California + 14 more

Conditions: Asthma
Interventions: Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo; Drug
Lead sponsor: West-Ward Pharmaceutical; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Rheumatoid Arthritis
Interventions: Itacitinib, Itacitinib Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Palm Desert, California • Pasadena, California • Lake Mary, Florida + 14 more

Conditions: Type 2 Diabetes
Interventions: SK-0403, Placebo, Sitagliptin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more

Conditions: Schizophrenia
Interventions: bitopertin [RO4917838], olanzapine, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more

Conditions: Spinocerebellar Ataxias
Interventions: BHV-4157; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Systemic Inflammation (hsCRP), Healthy Aging, Vitality, Healthy Adult Participants
Interventions: Apple Extract, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraland USA, Inc.; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin + Placebo, Apixaban + Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 3,608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more

Conditions: Chikungunya Virus Infection
Interventions: Placebo, VRC-CHKVLP059-00-VP; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Atlanta, Georgia • Iowa City, Iowa • Houston, Texas

Conditions: Leg Cramp, Nocturnal
Interventions: Theraworx, Placebo; Device · Other
Lead sponsor: Sport and Spine Rehab Clinical Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Colitis, Ulcerative
Interventions: Placebo, JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily, JNJ-54781532 75 mg twice daily; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: La Jolla, California • Thornton, Colorado • Ann Arbor, Michigan + 12 more

Conditions: HCV Infection
Interventions: GS-9450, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 51
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk), Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark); Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Mahwah, New Jersey

Conditions: Asthma
Interventions: IPL512,602 20 mg once daily, IPL512,602 Matching Placebo once daily; Drug
Lead sponsor: Inflazyme Pharmaceuticals Ltd; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 5 more

Conditions: Fibroid Uterus, Abnormal Uterine Bleeding, Myoma;Uterus
Interventions: Tranexamic Acid, Placebos; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Unipolar Depression
Interventions: Bright light therapy, dim red light; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

Efficacy and Safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women With High Stress and Anxiety: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Phase I Trial of Measles Vectored Chikungungya Vaccine

Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies

Bright Light Therapy for Depressed Geriatric Inpatients